Precision medicine in diabetes: A non-invasive prenatal diagnostic test for the determination of fetal glucokinase mutations

8Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Hyperglycemia caused by mutations in the glucokinase gene, GCK, is the most common form of monogenic diabetes. Prenatal diagnosis is important, as it impacts on treatment. This study reports a monogenic non-invasive prenatal diagnostic (NIPD-M) test on cell-free DNA in maternal plasma using the relative haplotype dosage. In three pregnancies of two families with known maternal GCK mutations, the fetal genotype was determined unambiguously already at 12 weeks of gestation. In summary, proof is provided of the feasibility for NIPD-M in GCK diabetes.

Cite

CITATION STYLE

APA

Nouspikel, T., Blouin, J. L., Puder, J. J., Köhler Ballan, B., & Schwitzgebel, V. M. (2022). Precision medicine in diabetes: A non-invasive prenatal diagnostic test for the determination of fetal glucokinase mutations. Journal of Diabetes Investigation, 13(2), 256–261. https://doi.org/10.1111/jdi.13656

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free